Notice2024-22863
Notice of Diabetes Mellitus Interagency Coordinating Committee Meeting
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
October 3, 2024
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The Diabetes Mellitus Interagency Coordinating Committee (DMICC) will hold a hybrid (virtual/in-person) meeting on November 12, 2024. The topic for this meeting will be "Opportunities for Research Supported by the Special Statutory Funding Program for Type 1 Diabetes Research." The meeting is open to the public.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 192 (Thursday, October 3, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 192 (Thursday, October 3, 2024)]
[Notices]
[Page 80576]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-22863]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Notice of Diabetes Mellitus Interagency Coordinating Committee
Meeting
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Diabetes Mellitus Interagency Coordinating Committee
(DMICC) will hold a hybrid (virtual/in-person) meeting on November 12,
2024. The topic for this meeting will be ``Opportunities for Research
Supported by the Special Statutory Funding Program for Type 1 Diabetes
Research.'' The meeting is open to the public.
DATES: The meeting will be held on November 12, 2024, from 8:30 a.m. to
5:00 p.m. EDT.
ADDRESSES: This hybrid meeting will convene virtually via the Zoom
online video conferencing platform or in person at: National Institutes
of Health Campus, Natcher Conference Center (Building 45), Room E1/E2,
45 Center Drive, Bethesda, MD 20894. Attendance for the meeting will be
accessible to members of the public who register at <a href="http://www.scgcorp.com/DMICC2024/Registration">www.scgcorp.com/DMICC2024/Registration</a> by November 5, 2024.
FOR FURTHER INFORMATION CONTACT: For further information concerning
this meeting, including a draft agenda, which will be posted when
available, see the DMICC website, <a href="https://www.niddk.nih.gov/about-niddk/advisory-coordinating-committees/diabetes-mellitus-interagency-coordinating-committee-dmicc?dkrd=lgdmn0022">https://www.niddk.nih.gov/about-niddk/advisory-coordinating-committees/diabetes-mellitus-interagency-coordinating-committee-dmicc?dkrd=lgdmn0022</a>, or contact Dr. William
Cefalu, Executive Secretary of the Diabetes Mellitus Interagency
Coordinating Committee, National Institute of Diabetes and Digestive
and Kidney Diseases, 6707 Democracy Boulevard, Democracy 2, Room 6037,
Bethesda, MD 20892, telephone: 301-435-1011; email: <a href="/cdn-cgi/l/email-protection#36525b5f5555765b575f5a18585f5e18515940"><span class="__cf_email__" data-cfemail="afcbc2c6ccccefc2cec6c381c1c6c781c8c0d9">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: In accordance with 42 U.S.C. 285c-3, the
DMICC, chaired by the National Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK) and comprising members of the Department of
Health and Human Services and other federal agencies that support
diabetes-related activities, facilitates cooperation, communication,
and collaboration on diabetes among government entities. DMICC
meetings, held several times a year, provide an opportunity for
Committee members to learn about and discuss current and future
diabetes programs in DMICC member organizations and to identify
opportunities for collaboration. The November 12, 2024 DMICC meeting
will focus on ``Opportunities for Research Supported by the Special
Statutory Funding Program for Type 1 Diabetes Research.''
Any interested person may file written comments with the Committee
by forwarding their statement to the contact person listed on this
notice. The statement should include the name, address, telephone
number and, when applicable, the business or professional affiliation
of the interested person. Because of time constraints for the meeting,
there will not be time on the agenda for oral comments from members of
the public.
Members of the public who would like to receive email notification
about future DMICC meetings should register for the listserv available
on the DMICC website, <a href="https://www.niddk.nih.gov/about-niddk/advisory-coordinating-committees/diabetes-mellitus-interagency-coordinating-committee-dmicc?dkrd=lgdmn0022">https://www.niddk.nih.gov/about-niddk/advisory-coordinating-committees/diabetes-mellitus-interagency-coordinating-committee-dmicc?dkrd=lgdmn0022</a>.
Dated: September 24, 2024.
William T. Cefalu,
Director, Division of Diabetes, Endocrinology, and Metabolic Diseases,
National Institute of Diabetes and Digestive and Kidney Diseases,
National Institutes of Health.
[FR Doc. 2024-22863 Filed 10-2-24; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on October 3, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.